Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate

BACKGROUND: SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European Medicines Agency, assessment of cognitive function was a predefined safety out...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CNS Drugs
Hlavní autoři: Coghill, David R., Banaschewski, Tobias, Bliss, Caleb, Robertson, Brigitte, Zuddas, Alessandro
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2018
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5843702/
https://ncbi.nlm.nih.gov/pubmed/29383572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-017-0487-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky